EUCTR2009-015476-98-GB进行中（未招募）1 期
X-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment - LUX-Breast 1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 745
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •patients with metastatic HER2-positive breast cancer
- •no prior HER2-targeted treatment other than trastuzumab allowed
- •no prior vinorelbine treatment allowed
- •patients should have received prior taxane and/or anthracycline containing chemotherapy
- •patients must have progressed on one prior trastuzumab treatment, i.e. patients with:
- •- First-line metastatic breast cancer failing on adjuvant trastuzumab or within 12 months of completion of adjuvant trastuzumab treatment; prior trastuzumab treatment must have been at least 9 weeks
- •- Second-line metastatic breast cancer failing on first-line trastuzumab or within 6 months of completion of first-line trastuzumab treatment; prior trastuzumab treatment must have been at least 6 weeks
- •Must have (archived) tumour tissue sample available for central re-assessment of HER2-status and prove HER2-positive. HER2 status must be confirmed by sponsor contracted laboratory prior to randomisation.
- •At least one measurable lesion according to RECIST 1.1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 680
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1.Prior treatment with EGFR/HER2-targeted small molecules or antibodies other than trastuzumab
- •2.Prior treatment with vinorelbine
- •3.Known pre-existing interstitial lung disease
- •4.Radiotherapy, chemotherapy, hormone therapy, immunotherapy or surgery (other than biopsy) within 4 weeks (2 weeks for hormone therapy, 3 weeks for trastuzumab) prior to randomisation.
- •5.Active brain metastases (defined as stable for <4 weeks and/or symptomatic and/or requiring changes of treatment with anticonvulsants or steroids within the past 4 weeks and/or leptomeningeal disease). Patients with known history of brain metastases should undergo a baseline brain image to ensure that the disease is stable
- •6.Any other current malignancy or malignancy diagnosed within the past five (5) years (other than bilateral primary breast cancer, metastases to the contralateral breast, non-melanomatous skin cancer and in situ cervical cancer).
- •7.Significant or recent acute gastrointestinal disorders with diarrhoea as a major symptom e.g. Crohn's disease, malabsorption or CTC grade =2 diarrhoea of any aetiology.
- •8.History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation.
- •9.Cardiac left ventricular function with resting ejection fraction of less than 50%.
- •10.Any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test drug.
- •11.Absolute neutrophil count (ANC) < 1500 / mm³.
- •12.Platelet count < 100,000 / mm³
- •13.Calculated creatinine clearance < 60 ml / min (using preferably Cockcroft-Gault formula for GFR estimate, see appendix 1) or serum creatinine > 1.5 times upper limit of normal.
- •14.Bilirubin > 1.5 times upper limit of normal.
- •15.Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal (ULN) (if related to liver metastases > 5 times ULN).
- •16.Women of childbearing potential, unwilling to use a medically acceptable method of contraception during the trial, see Section 5.2.2.4.
- •17.Pregnancy or breast-feeding.
- •18.Patients unable to comply with the protocol.
- •19.Known hepatitis B infection, known hepatitis C infection or known HIV carrier.
- •20.Known or suspected active drug or alcohol abuse.
- •21.Requirement for treatment with any of the prohibited concomitant medications listed in section 4.2.2.1.
- •22.Any contraindications for therapy with vinorelbine or trastuzumab.
- •23.Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs.
- •24.Use of any investigational drug within 4 weeks of randomisation.
研究者
相似试验
已完成
3 期
X-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatmentmammacarcinoma10006291Breast cancerNL-OMON34674Boehringer Ingelheim15
进行中（未招募）
1 期
X-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment - LUX-Breast 1patients with metastatic HER2 over-expressing breast cancerMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleMedDRA version: 12.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 12.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-015476-98-FRBOEHRINGER INGELHEIM FRANCE780
进行中（未招募）
不适用
X-Breast 1; An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment - LUX-Breast 1patients with metastatic HER2 over-expressing breast cancerMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleMedDRA version: 12.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 12.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2009-015476-98-FIBoehringer Ingelheim780
进行中（未招募）
1 期
Afatinib (BIBW 2992) in HER2 Overexpressing Metastatic Breast Cancer Patientspatients with metastatic HER2 over-expressing breast cancerMedDRA version: 16.0Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015476-98-CZBoehringer Ingelheim RCV GmbH & Co KG780
进行中（未招募）
1 期
Afatinib (BIBW 2992) in HER2 Overexpressing Metastatic Breast Cancer Patientspatients with metastatic HER2 over-expressing breast cancerMedDRA version: 14.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015476-98-NLBoehringer Ingelheim780